Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part.

Image courtesy of Shutterstock

The first four participants have already received this experimental vaccine at the Churchill Hospital in  Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.

In an initial study led by Professor Freddie Hamdy in Oxford and Professor Jim Catto in Sheffield, the team will vaccinate 48 men with low or intermediate risk prostate cancer to document the safety of the new vaccine and measure how well the immune system to responds to it. If successful, then future larger-scale studies will assess the effectiveness of the vaccine.

Read more

Similar stories

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.